Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
IPO Year:
Exchange: NYSE
Website: edwards.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies |
7/31/2024 | Neutral → Outperform | Daiwa Securities | |
7/29/2024 | Underperform → Peer Perform | Wolfe Research | |
7/25/2024 | $100.00 → $70.00 | Buy → Hold | TD Cowen |
7/25/2024 | $105.00 → $75.00 | Buy → Neutral | BofA Securities |
7/25/2024 | $102.00 → $70.00 | Outperform → Neutral | Robert W. Baird |
7/25/2024 | $105.00 → $72.00 | Overweight → Neutral | JP Morgan |
7/25/2024 | $110.00 → $82.00 | Buy → Hold | Truist |
5/30/2024 | $107.00 | Buy | Goldman |
5/22/2024 | $98.00 → $105.00 | Neutral → Buy | Citigroup |
NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE:EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The data demonstrated that the 456 patients managed with Cordella in the study experienced a meaningful reduction in one-year HF hospitalization and all-cause mortality rate (36 events per 100 patients versus the 70 events per 100 patien
Company announces $1 billion share repurchase Edwards Lifesciences (NYSE:EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE:BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share repurchases. "Critical Care has made significant contributions to our company and has a long history of innovation. We are grateful to the team for their commitment to improving patient outcomes globally," said Bernard Zovighian, Edwards' CEO. "The sale of Critical Care reflects our sharpened focus as a structural heart
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves as compared to those receiving surgical aortic valve replacement (SAVR). "Women are an underrepresented group in the diagnosis and treatment of severe aortic stenosis and this landmark study provides important insights into their treatment options," said Hélène Eltchaninoff, M.D., head of
Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving an
Edwards Lifesciences (NYSE:EW) today announced investments that reflect the company's deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. JenaValve presented positive results of its U.S. pivotal trial for the treatment of symptomatic, severe AR in high-risk patients late last year. As the pioneer in valve innovation for more than 60 years, Edwar
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent patient outcomes; NCD process on track Critical Care sale expected to close late Q3 2024 Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMT
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives t
Edwards Lifesciences (NYSE:EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards' existing mitral innovations, the acquisition enhances the company's TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president, Daveen Chopra. "Building on ou
Edwards Lifesciences (NYSE:EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient's annulus size or sex. These data were presented during the late-breaking clinical sessions at New York Valves 2024: The Structural Heart Summit. As part of this analysis, contemporary patient data with long-term follow up from the PARTNER 3 randomized controlled trial and PARTNER 2 S3i Trial were examin
Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS Expands BD's portfolio of smart connected care solutions with complementary and broad set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline Critical Care to operate as a separate business unit within BD's Medical segment, based in Irvine, Calif. and led by Katie SzymanFRANKLIN LAKES, N.J., June 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE:EW),
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
S-8 - Edwards Lifesciences Corp (0001099800) (Filer)
10-Q - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
11-K - Edwards Lifesciences Corp (0001099800) (Filer)
11-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
3 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
Jefferies downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $70.00 from $85.00 previously
Daiwa Securities upgraded Edwards Lifesciences from Neutral to Outperform
Wolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform
TD Cowen downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $70.00 from $100.00 previously
BofA Securities downgraded Edwards Lifesciences from Buy to Neutral and set a new price target of $75.00 from $105.00 previously
Robert W. Baird downgraded Edwards Lifesciences from Outperform to Neutral and set a new price target of $70.00 from $102.00 previously
JP Morgan downgraded Edwards Lifesciences from Overweight to Neutral and set a new price target of $72.00 from $105.00 previously
Truist downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $82.00 from $110.00 previously
Goldman initiated coverage of Edwards Lifesciences with a rating of Buy and set a new price target of $107.00
Citigroup upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $105.00 from $98.00 previously
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $70.
Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $100 to $90.
U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 0.5% on Thursday. Shares of Ford Motor Company (NYSE:F) fell sharply in today's pre-market trading following a second-quarter earnings miss. Ford reported second-quarter revenue of $47.8 billion, up 6% year-over-year. The revenue beat a Street consensus estimate of $44 billion according to data from Benzinga Pro. The company reported quarterly earnings per share of 47 cents, missing a Street consensus estimate of 68 cents. Ford Motor shares dipped 13% to $11.90 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Edwards Lifescience
EW: -24% | Edwards Lifesciences shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company acquired JenaValve and Endotronix. MXL: -27% | MaxLinear shares are trading lower after the company reported worse-than-expected Q2 financial results. POAI: 117% | Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $77.
Piper Sandler analyst Adam Maeder maintains Edwards Lifesciences (NYSE:EW) with a Neutral and lowers the price target from $88 to $73.
B of A Securities analyst Travis Steed downgrades Edwards Lifesciences (NYSE:EW) from Buy to Neutral and lowers the price target from $105 to $75.
JP Morgan analyst Robbie Marcus downgrades Edwards Lifesciences (NYSE:EW) from Overweight to Neutral and lowers the price target from $105 to $72.
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech space could once again drag the broader market after a few disappointing earnings reports from the likes of Franco-Italian chipmaker STMicroelectronics N.V. (NYSE:STM), which predominantly supplies to the automotive end market, and semiconductor test-equipment company Teradyne, Inc. (NASDAQ:TER). Traders may also stay glued to second-quarter GDP data to confirm the slowdown suggested by some recent data does not point to a hard landing. That said, bond yields are dipping as the market, factori
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent patient outcomes; NCD process on track Critical Care sale expected to close late Q3 2024 Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMT
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives t
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT and Surgical; confident in TAVR guidance Critical Care spin-off on track; raising 2024 sales guidance "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategi
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying moderate AS patients Received early FDA approval for EVOQUE; ongoing European launch of EVOQUE Executed $400 million accelerated share repurchase in Q4; $867 million repurchased in 2023 Confident in 2024 gui
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing l
Edwards Lifesciences Corporation (NYSE:EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference. Highlights of today's conference include: Expecting early completion of enrollment in PROGRESS, studying moderate AS patients, in early 2024 Expecting data from EARLY TAVR, studying severe asymptomatic AS patients, at TCT 2024 Commercializing EVOQUE tricuspid valve in Europe; expecting U.S. approval mid-2024 Expecting CE Mark for SAPIEN M3 by the end of 2025 Reaffirming 2023 financial guidance Projecting 2024 global sales of $6.3 -
IRVINE, Calif., July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion; constant currency1 sales grew 12 percentAll product groups achieved double digit constant currency sales growth in Q2Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percentQ2 EPS of $0.50 (includes charge from previous IP agreement); adjusted1 EPS of $0.66Encouraging data from Edwards' Benchmark Registry at the EuroPCR medical congressNew 2023 constant c
IRVINE, Calif., July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards LifesciencesEdwards Lifesciences, is the global leader of patient-focused
IRVINE, Calif., April 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion; constant currency1 sales grew 13 percentQ1 TAVR sales grew 8 percent; constant currency sales grew 11 percentQ1 EPS of $0.56; adjusted1 EPS of $0.62Repurchased approximately $250 million of Edwards stock in Q1Completed enrollment of the transcatheter tricuspid valve replacement pivotal trialInitiated launch of the SAPIEN 3 Ultra RESILIA valve in Japan late last month
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi